Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder. It also provides arthroscopic enabling technologies for healthcare providers comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue. In addition, the company offers trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; robotics-assisted surgery, various products, and technologies to assist in surgical treatment of the ear, nose, and throat; knee implant products for specialized knee replacement procedures; and hip implant products for the reconstruction of hip joints. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration; and advanced wound devices, such as traditional and single-use negative pressure wound therapy and hydrosurgery systems. The company primarily serves the providers of medical and surgical treatments and services. Smith & Nephew plc was founded in 1856 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange LON
Industry Medical Appliances & Equipment
Sub-IndustryN/A
SectorMedical
SymbolLON:SN
CUSIPN/A
Phone+44-20-74017646
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins19.56%
Return on Equity21.42%
Return on Assets12.38%
Miscellaneous
EmployeesN/A
Outstanding Shares891,150,000
Market Cap£11,630.00
Smith & Nephew (LON:SN) Frequently Asked Questions
What is Smith & Nephew's stock symbol?
Smith & Nephew trades on the London Stock Exchange (LON) under the ticker symbol "SN."
How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?
Smith & Nephew declared a dividend on Thursday, February 8th. Stockholders of record on Thursday, April 5th will be given a dividend of GBX 0.23 per share on Wednesday, May 9th. This represents a dividend yield of 1.34%. The ex-dividend date of this dividend is Thursday, April 5th. This is an increase from Smith & Nephew's previous dividend of $0.12. The official announcement can be accessed at this link. View Smith & Nephew's Dividend History.
What price target have analysts set for SN?
10 brokers have issued 12 month target prices for Smith & Nephew's shares. Their forecasts range from GBX 1,160 to GBX 1,530. On average, they anticipate Smith & Nephew's share price to reach GBX 1,394.45 in the next twelve months. This suggests a possible upside of 4.5% from the stock's current price. View Analyst Ratings for Smith & Nephew.
What is the consensus analysts' recommendation for Smith & Nephew?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 2 sell ratings, 4 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
Who are some of Smith & Nephew's key competitors?
Some companies that are related to Smith & Nephew include Consort Medical (CSRT), Corindus Vascular Robotics (CVRS), Ekf Diagnostics (EKF), Bioquell (BQE), Immunodiagnostic Systems (IDH), Zecotek Photonics (ZMS), Theralase Technologies (TLT), LiDCO Group (LID), Medaphor Group (MED), InspireMD (NSPR), Lucid (LCDX), Verisante Technology (VRS) and Deltex Medical Group (DEMG).
Who are Smith & Nephew's key executives?
Smith & Nephew's management team includes the folowing people:
- Mr. Graham Timothy Baker, CFO & Exec. Director (Age 50)
- Mr. Namal Nawana, CEO & Exec. Director (Age 47)
- Mr. Matthew R. Stober, Pres of Global Operations (Age 50)
- Mr. Arjun Rajaratnam, Chief Compliance Officer
- Ms. Catheryn O'Rourke, Chief Legal Officer (Age 45)
Has Smith & Nephew been receiving favorable news coverage?
Media coverage about SN stock has been trending positive recently, according to Accern. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Smith & Nephew earned a media sentiment score of 0.35 on Accern's scale. They also assigned news stories about the company an impact score of 45.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
How do I buy shares of Smith & Nephew?
Shares of SN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Smith & Nephew's stock price today?
One share of SN stock can currently be purchased for approximately GBX 1,335.
How big of a company is Smith & Nephew?
Smith & Nephew has a market capitalization of £11.63 billion.
How can I contact Smith & Nephew?
Smith & Nephew's mailing address is 15 Adam Street, LONDON, WC2N 6LA, United Kingdom. The company can be reached via phone at +44-20-74017646.
MarketBeat Community Rating for Smith & Nephew (LON SN)
MarketBeat's community ratings are surveys of what our community members think about Smith & Nephew and other stocks. Vote "Outperform" if you believe SN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SN will underperform the S&P 500 over the long term. You may vote once every thirty days.
